CRISPR Base Editing Therapeutics 2026 — PatSnap Eureka
CRISPR Base Editing Therapeutic Technology Landscape
From adenine and cytosine deaminase chemistry to LNP-delivered cardiovascular programmes, the base editing patent landscape is one of the fastest-moving in genomic medicine. Discover which assignees, disease areas, and delivery technologies are shaping the field in 2026.
What Is CRISPR Base Editing and Why Does It Matter?
CRISPR base editing is a precision genome modification approach that uses a deaminase enzyme fused to a Cas nickase to chemically convert one DNA base to another without making double-strand breaks. The two primary classes are adenine base editors (ABEs), which convert A·T to G·C base pairs, and cytosine base editors (CBEs), which convert C·G to T·A. This makes base editing more precise and potentially safer than traditional CRISPR-Cas9, which cuts both strands of DNA and relies on error-prone repair pathways.
The technology was pioneered at the Broad Institute and Harvard, with David Liu's laboratory developing the first ABEs using TadA deaminase variants — including the landmark ABE8e variant with improved editing efficiency. CBEs use APOBEC1 or other cytosine deaminase enzymes, and uracil glycosylase inhibitors (UGIs) are often co-expressed to improve editing efficiency by blocking repair of uracil intermediates. According to published literature, base editors can achieve high on-target efficiency with reduced bystander edits and reduced indel frequency compared to nuclease-based approaches.
The commercial translation of base editing is accelerating rapidly. Beam Therapeutics — the leading commercial filer in this space — has built a broad portfolio spanning multiplexed editing, LNP delivery, T cell engineering, metabolic disease, and haemoglobin disorders. Verve Therapeutics has focused its entire pipeline on cardiovascular disease via hepatocyte-targeted LNP delivery. The life sciences patent landscape reflects this bifurcation between platform-building (Broad/Beam) and indication-focused strategies (Verve, Editas).
For R&D teams navigating freedom-to-operate or competitive intelligence in this space, patent analytics are essential. The density of overlapping claims — particularly between the Broad Institute and Beam Therapeutics — creates a complex IP environment that requires systematic monitoring.
Disease Areas Targeted by Base Editing Patents
Patent filings reveal a broad and expanding set of disease indications, from haematology and cardiovascular disease to neurology and rare metabolic disorders.
Sickle Cell Disease & Beta-Thalassemia
The most patent-dense disease area in base editing. Methods involve correcting the HBB gene point mutation responsible for sickle cell disease, or introducing mutations in the BCL11A erythroid enhancer to reactivate fetal hemoglobin (HbF) expression. Beam Therapeutics, St. Jude Children's Research Hospital, and Graphite Bio have all filed in this space. Ex vivo base editing of haematopoietic stem cells (HSCs) followed by reinfusion is the dominant approach.
BCL11A enhancer · HBB correction · HbF reactivationPCSK9 & ANGPTL3 Gene Disruption
Verve Therapeutics has built a focused portfolio around using adenine base editors delivered via LNPs to hepatocytes to permanently disable PCSK9 and ANGPTL3 genes, reducing serum LDL cholesterol and triglyceride levels as a one-time treatment. Beam Therapeutics has also filed cytosine base editor approaches targeting familial hypercholesterolaemia and hypertriglyceridaemia. The WHO identifies cardiovascular disease as the leading cause of global mortality, underpinning the commercial rationale.
PCSK9 · ANGPTL3 · LDL reduction · one-time treatmentT Cell Engineering for Adoptive Cell Therapy
Beam Therapeutics has filed extensively on using base editors to modify T cells and NK cells for adoptive cell therapy. The approaches involve disrupting genes in immune checkpoint pathways and T cell exhaustion mechanisms to enhance anti-tumour activity. Multiplexed base editing — simultaneously editing multiple genomic loci using multiple guide RNAs — is a key enabling technology for engineering complex cell therapy products.
Multiplexed editing · immune checkpoint · T cell exhaustionHuntington's, Parkinson's & Alzheimer's
Prime Medicine has filed on prime editing and base editing systems for correcting mutations associated with Huntington's disease, Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. The methods involve delivering editing systems to the brain or cells of the nervous system. CNS delivery remains a key technical challenge, with AAV vectors the primary route explored in patent filings.
CNS delivery · AAV · neurodegenerative mutationsLeber's Congenital Amaurosis & Retinal Dystrophies
The Broad Institute and Editas Medicine have both filed on delivering base editors via AAV or LNPs to the retina or other ocular tissues to correct mutations associated with Leber's congenital amaurosis, Stargardt disease, and other retinal dystrophies. The eye is an attractive target for in vivo base editing due to its immune-privileged status and accessibility.
LCA · Stargardt · retinal delivery · AAVInborn Errors of Metabolism & DMD
Precision Biosciences has filed on correcting point mutations in phenylketonuria, methylmalonic acidaemia, and propionic acidaemia. Beam Therapeutics has filed on treating Duchenne muscular dystrophy (DMD) by correcting mutations in the dystrophin gene or introducing stop codon readthrough mutations. Decibel Therapeutics has filed on base editing for hereditary hearing loss targeting KCNQ4 and GJB2 mutations.
PKU · DMD · dystrophin · KCNQ4 · GJB2Base Editing Patent Landscape: Data Visualised
Key metrics from the CRISPR base editing patent corpus, analysed via PatSnap Eureka.
Patent Filings by Disease Area
Haematology leads the base editing patent corpus, followed by cardiovascular and oncology/cell therapy indications.
Delivery Modality Distribution
LNP-based in vivo delivery and ex vivo electroporation of HSCs/T cells dominate, with AAV used primarily for ocular and muscular targets.
Base Editor Delivery: Key Patent Filings by Modality
Three delivery modalities dominate the patent landscape, each suited to distinct tissue targets and therapeutic contexts.
| Delivery Modality | Key Assignee(s) | Target Tissue | Disease Application | Patent Status |
|---|---|---|---|---|
| Lipid Nanoparticle (LNP) mRNA + gRNA encapsulated | Beam Therapeutics Verve Therapeutics | Hepatocytes (liver) | Cardiovascular (PCSK9, ANGPTL3), ATTR amyloidosis, metabolic disorders | Active Filing |
| Ex Vivo Electroporation mRNA + gRNA to cells | Beam Therapeutics St. Jude / Graphite Bio | HSCs, T cells, NK cells | Sickle cell disease, beta-thalassaemia, adoptive cell therapy | Clinically Advanced |
| AAV Vector Split-intein systems | Editas Medicine Broad Institute | Retina, muscle, CNS | Retinal dystrophies, DMD, neurological diseases | Active Filing |
| Ionisable Lipid LNP Novel lipid formulations | Verve Therapeutics Alnylam Pharmaceuticals | Hepatocytes (liver) | Hypercholesterolaemia, hypertriglyceridaemia | Active Filing |
Monitor Delivery Technology Patents in Real Time
Set alerts for new LNP, AAV, and electroporation filings in base editing with PatSnap Eureka.
Safety, Precision & Off-Target Mitigation
A significant cluster of base editing patents addresses the critical challenge of off-target deamination, bystander editing, and unintended RNA modifications.
High-Fidelity TadA Variants (ABE8e)
The Broad Institute and David Liu have filed patents on TadA deaminase variants — including ABE8e — with mutations that reduce off-target RNA editing and improve precision of DNA editing. These high-accuracy ABEs achieve single-nucleotide precision by restricting deaminase activity to the intended DNA base within the editing window.
Narrowed Editing Windows
High-fidelity base editors with reduced bystander editing effects comprise deaminase variants with narrowed editing windows, including variants of TadA and APOBEC deaminases engineered to have restricted activity windows. Optimised guide RNAs are also used to promote selective deamination in the desired editing window and reduce bystander edits.
Machine Learning-Guided gRNA Optimisation
The Broad Institute has filed on using machine learning models trained on large datasets of base editing outcomes to predict the efficiency and specificity of base editing at different genomic loci, and to optimise guide RNA design and base editor selection for therapeutic applications. This computational approach reduces empirical screening burden.
PAM Compatibility Expansion (SpRY)
Wild-type SpCas9 requires an NGG PAM sequence, limiting accessible genomic locations. Patents from the Broad Institute covering SpRY and SpCas9-NG variants that can recognise a broader range of PAM sequences significantly expand the number of targetable genomic sites, enabling base editing at disease-relevant loci previously inaccessible to conventional base editors.
Key Patent Assignees & Portfolio Strategies
The Broad Institute and President and Fellows of Harvard College together represent the dominant patent assignee bloc in base editing, covering adenine base editors (ABEs), cytosine base editors (CBEs), high-fidelity variants, PAM-broadened editors (SpRY, SpCas9-NG), guide RNA optimisation, machine learning-guided design, and RNA base editing via Cas13-ADAR fusions. Their portfolio is foundational — most commercial programmes require licences to or design-arounds of Broad/Harvard claims.
Beam Therapeutics holds the second-largest commercial portfolio, with patents spanning multiplexed base editing, LNP delivery formulations, mRNA composition optimisation, T cell and NK cell electroporation, haematopoietic stem cell editing (BCL11A enhancer, HBB), metabolic disease (PCSK9, ANGPTL3 via CBE), ATTR amyloidosis, DMD, and small molecule-controlled base editing systems. Beam's strategy is to build a broad, indication-agnostic platform.
Verve Therapeutics has adopted a focused, indication-specific strategy, with its entire portfolio concentrated on cardiovascular disease via LNP-delivered ABEs targeting PCSK9 and ANGPTL3 in hepatocytes. Their filings include novel ionisable lipid LNP formulations optimised for hepatocyte delivery. Case studies from the PatSnap platform illustrate how IP teams track competitive cardiovascular gene therapy portfolios.
Editas Medicine has filed on AAV-mediated delivery of base editors for monogenic diseases including DMD and retinal dystrophies, as well as CRISPR-based sickle cell disease correction and in vivo ocular base editing. Prime Medicine has filed on both prime editing and base editing for neurological diseases, and on inducible base editing systems. St. Jude Children's Research Hospital and Graphite Bio have filed on BCL11A enhancer editing for haemoglobinopathies. For systematic competitive monitoring across all these assignees, PatSnap Analytics provides real-time alerting on new filings. NIH research coverage tracks the clinical translation of these academic-origin technologies.
CRISPR Base Editing Therapeutics — Key Questions Answered
CRISPR base editing uses a deaminase enzyme fused to a Cas nickase to chemically convert one DNA base to another — for example adenine to guanine (ABEs) or cytosine to thymine (CBEs) — without making double-strand breaks. This makes it more precise and potentially safer than traditional CRISPR-Cas9, which cuts both strands of DNA and relies on error-prone repair pathways.
The Broad Institute and President and Fellows of Harvard College together represent the dominant patent assignee bloc in base editing, covering adenine base editors (ABEs), cytosine base editors (CBEs), high-fidelity variants, PAM-broadened editors, and guide RNA optimisation. Beam Therapeutics holds the second-largest portfolio, with patents spanning multiplexed editing, LNP delivery, T cell engineering, metabolic disease, and haemoglobin disorders. Verve Therapeutics focuses specifically on cardiovascular applications via LNP-delivered ABEs targeting PCSK9 and ANGPTL3.
Patent filings reveal activity across haematology (sickle cell disease, beta-thalassemia via BCL11A enhancer editing and HBB correction), cardiovascular disease (PCSK9 and ANGPTL3 gene disruption to reduce LDL cholesterol), oncology (T cell engineering for adoptive cell therapy), neurology (Huntington's, Parkinson's, Alzheimer's), ophthalmology (Leber's congenital amaurosis and other retinal dystrophies), metabolic disorders (familial hypercholesterolaemia, phenylketonuria, methylmalonic acidaemia), musculoskeletal disease (Duchenne muscular dystrophy via dystrophin gene correction), and hearing loss (KCNQ4, GJB2 mutations).
Two primary delivery modalities dominate the patent landscape. Lipid nanoparticles (LNPs) encapsulate mRNA encoding the base editor plus guide RNA and are optimised for in vivo delivery to hepatocytes — used by Beam Therapeutics and Verve Therapeutics for liver-targeted programmes. Adeno-associated virus (AAV) vectors, including split-intein AAV systems, are used for delivery to muscle, retina, and other tissues — used by Editas Medicine. Ex vivo electroporation is used to deliver base editors to haematopoietic stem cells (HSCs) and T cells for cell therapy approaches.
Key challenges include off-target DNA deamination at bystander cytosines or adenines within the editing window, unintended RNA editing by the deaminase component, and indel formation. Solutions patented include high-fidelity Cas9 variants with restricted editing windows, TadA variants (such as ABE8e) with reduced RNA editing activity, modified guide RNAs to minimise bystander edits, machine learning-guided guide RNA optimisation, uracil glycosylase inhibitors (UGIs) for CBE efficiency, and anti-CRISPR protein-based safety switches.
Wild-type SpCas9 requires an NGG PAM sequence, which limits the genomic locations accessible to base editors. Patents from the Broad Institute covering SpRY and SpCas9-NG variants that can recognise a broader range of PAM sequences significantly expand the number of targetable genomic sites, enabling base editing at disease-relevant loci that were previously inaccessible.
Still have questions? Let PatSnap Eureka search the base editing patent corpus for you.
Ask Eureka About Base Editing PatentsMap the Entire CRISPR Base Editing Patent Landscape
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D and stay ahead of the base editing IP frontier.
References
- Base Editing Guide RNAs — US20220220467A1 — The Broad Institute / Harvard College. Optimised guide RNAs for selective deamination with reduced bystander edits and indel frequency.
- Adenine Base Editors Comprising Variants with Improved Properties — US20210269786A1 — The Broad Institute / Harvard College. ABE8e TadA variant with improved editing efficiency and reduced off-target edits.
- Base Editing of Haematopoietic Stem Cells to Treat Sickle Cell Disease — WO2022067130A1 — Beam Therapeutics Inc. Ex vivo HSC base editing for HBB correction and HbF reactivation.
- Base Editors with Diversified PAM Compatibility — WO2021158921A1 — The Broad Institute / Harvard College. SpRY and SpCas9-NG variants for broader genomic targeting.
- Use of Base Editors for Cancer Immunotherapy — WO2020181180A1 — Beam Therapeutics Inc. T cell engineering via base editing for adoptive cell therapy.
- Cytosine Base Editors for Treatment of Metabolic Disorders — WO2022266446A2 — Beam Therapeutics Inc. CBEs targeting PCSK9 and ANGPTL3 for lipid disorders.
- Base Editing Using LNPs for Cardiovascular Disease — WO2023183589A1 — Verve Therapeutics Inc. LNP delivery of ABEs to hepatocytes for PCSK9/ANGPTL3 editing.
- AAV-Mediated Delivery of Base Editors for Monogenic Diseases — WO2022140691A1 — Editas Medicine Inc. Split-intein AAV systems for DMD and retinal dystrophies.
- Lipid Nanoparticles for Delivery of Base Editors — WO2022204508A1 — Beam Therapeutics Inc. LNP compositions for mRNA-encoded base editor delivery.
- Prime Editing and Base Editing for Neurological Diseases — WO2023081756A1 — Prime Medicine Inc. Editing systems for Huntington's, Parkinson's, Alzheimer's.
- Base Editing with Reduced Off-Target Effects — WO2022174013A1 — The Broad Institute / Harvard College. High-fidelity Cas9 variants and ML-guided gRNA optimisation.
- High Fidelity Base Editors with Reduced Bystander Effects — WO2022178424A1 — David Liu / The Broad Institute. Narrowed-window TadA and APOBEC variants.
- Machine Learning Guided Base Editing for Therapeutic Applications — WO2023015309A1 — The Broad Institute / Harvard College. ML models for predicting base editing efficiency and specificity.
- NIH PubMed Central — CRISPR Base Editing Literature — Published research on base editing efficiency, specificity, and therapeutic applications.
- U.S. Food and Drug Administration (FDA) — Regulatory frameworks for advanced gene editing therapies and IND guidance.
- European Medicines Agency (EMA) — European regulatory framework for gene therapy advanced medicinal products.
- World Health Organization — Cardiovascular Diseases — Global burden of cardiovascular disease, supporting the therapeutic rationale for PCSK9/ANGPTL3 base editing programmes.
- NIH Research Matters — CRISPR Base Editing — NIH coverage of clinical translation of base editing technologies.
- European Patent Office (EPO) — European patent database for jurisdiction-specific base editing patent coverage.
All patent data and landscape analysis on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform, accessed via PatSnap Eureka.
PatSnap Eureka searches patents and research to answer instantly.